NEWS COMMENTARY

World's first Alzheimer's drug in 20 years gets conditionally approved in China

Published:
November 05, 2019
Coverage:
Digital Transformation More...
Activities:
Markets More...
Very important

The development of the drug, Oligomannate, was inspired by the observation that elderly people who consumed seaweed had an extremely low incidence of Alzheimer’s disease. Shanghai Green Valley Pharmaceuticals plans to launch the product in China by the end of the year, with global Phase 3 trials planned in the U.S., EU, and other parts of Asia to support regulatory submissions worldwide. This is an interesting development, as the drug is claimed to not just treat but potentially reverse the condition as well. Clients should wait for more data after product launch and from the global Phase 3 trials and note that the Chinese government's approval was not unconditional, indicating more data is still needed on long-term safety and efficacy.

For the original news article, click here .


Further Reading

ViroVet raises $6.7 million to bring its novel livestock vaccines closer to market

News Commentary | June 01, 2020

The funding round was led by Seventure Partners and included participation from PMV, Biotech Fund Flanders, Capricorn Partners, Agri Investment Fund, KU Leuven, Gemma Frisius Fund, and Vives II. ViroVet will use the funds to develop its PLLAV vaccine technology and enter the market. While ViroVet ... Not part of subscription

AbCellera Biologics

Company Snapshot | June 20, 2021

The company was started by Carl Hansen, Véronique Lecault, Kevin Heyries, Daniel Da Costa, and Oleh Petriv in 2012. To date, the company has raised approximately $780 million, most recently through an IPO that raised $483 million in December 2020. Among its investors, we emphasize Data Collective, ... To read more, click here.

Genevant enters partnership with Takeda for developing rare liver disease therapies

News Commentary | September 08, 2021

Genevant Sciences develops lipid nanoparticle (LNP) nucleic acid delivery techniques, which can be utilized for mRNA‑based applications including vaccines, protein production, and nonviral gene therapies. The two companies reached an agreement for Genevant to develop therapeutics for two undisclosed... Not part of subscription